QNCX
Quince Therapeutics Inc

6,231
Loading...
Loading...
News
all
press releases
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the poster...
Business Wire·5d ago
News Placeholder
More News
News Placeholder
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that the...
Business Wire·3mo ago
News Placeholder
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced that it will host...
Business Wire·8mo ago
News Placeholder
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that Dirk...
Business Wire·8mo ago
News Placeholder
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced that the U.S...
Business Wire·8mo ago
News Placeholder
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that it...
Business Wire·9mo ago
News Placeholder
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced the online...
Business Wire·9mo ago
News Placeholder
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced the appointment...
Business Wire·9mo ago
News Placeholder
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today provided an update on...
Business Wire·11mo ago
News Placeholder
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the...
Business Wire·11mo ago

Latest QNCX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.